Freestone Grove Partners LP Takes $53.42 Million Position in Elanco Animal Health Incorporated $ELAN

Freestone Grove Partners LP purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, HoldingsChannel.com reports. The firm purchased 2,170,681 shares of the company’s stock, valued at approximately $53,420,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ELAN. Man Group plc purchased a new position in Elanco Animal Health in the second quarter worth $2,432,000. Jupiter Topco LLC purchased a new stake in shares of Elanco Animal Health during the 2nd quarter worth $5,566,000. Hsbc Holdings PLC acquired a new position in shares of Elanco Animal Health during the 2nd quarter worth $1,540,000. Redwood Grove Capital LLC acquired a new position in shares of Elanco Animal Health during the 2nd quarter worth $37,538,000. Finally, Primecap Management Co. CA purchased a new position in shares of Elanco Animal Health in the 2nd quarter valued at about $1,118,402,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analysts Set New Price Targets

ELAN has been the subject of several recent analyst reports. TD Cowen raised their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. KeyCorp increased their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Finally, JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.09.

Insider Activity at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 40,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were acquired at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the acquisition, the director directly owned 188,647 shares in the company, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the completion of the acquisition, the chief financial officer owned 137,516 shares in the company, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 63,198 shares of company stock worth $1,473,109. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $25.09 on Thursday. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98. The firm has a market cap of $12.54 billion, a price-to-earnings ratio of -61.20, a price-to-earnings-growth ratio of 1.50 and a beta of 1.67. The company’s 50-day moving average is $24.61 and its two-hundred day moving average is $24.01. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.